PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Olutasidenib→

Olutasidenib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1887014-12-1
Molecular formula
C18H15ClN4O2
Molecular weight
354.79 g/mol
Drug class
Mutant isocitrate dehydrogenase-1 (IDH1) inhibitortargeted antineoplastic
Mechanism of action
Inhibits mutant IDH1 enzymes, reducing production of the oncometabolite 2-hydroxyglutarate. This promotes differentiation of leukaemic myeloid cells and reduces the abnormal epigenetic signalling driven by mutant IDH1.
Indications / reported uses
  • Treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) with a susceptible IDH1 mutation detected by an FDA-approved test; specialist haematology use

Sources: US DailyMed — REZLIDHIA (olutasidenib) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Olutasidenib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Olutasidenib Permitted Daily Exposure (PDE) report (the Olutasidenib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Olutasidenib Occupational Exposure Limit (OEL) report (the Olutasidenib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.